KDM2B and cancer: Conceptually, inhibiting lysine demethylases (KDMs) specific for H3K36me2, such as FBXL10 and FBXL11, is a potential strategy for treating cancers associated with loss-of-function NSD1 mutations, and inhibiting NSD2 may be effective for NSD2-hyperactive cancers.